Clinical trial

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

NCT03651271

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-10-17

PhasePHASE2

Study timeline

Study start (actual)2018-10-17Date precision: day

Registry last updated2024-02-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Metastatic Cancerunresolved

Advanced Prostate Cancerunresolved

Interventions

Nivolumab MonotherapyBIOLOGICAL

Nivolumab and Ipilimumab and Combination for Metastatic CancerBIOLOGICAL

Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate CancerBIOLOGICAL

Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate CancerBIOLOGICAL

Sponsors & collaborators

Parker Institute for Cancer Immunotherapylead sponsor

Bristol-Myers Squibbcollaborator

Cancer Research Institute, New York Citycollaborator

Mapped research locations

New YorkNew York, United States1 HoustonTexas, United States1 BostonMassachusetts, United States1 Los AngelesCalifornia, United States1 San FranciscoCalifornia, United States1 Palo AltoCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03651271 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.